Tomasz Lawniczek

“Basel is the heart of our European growth – a place where science, talent and collaboration uniquely converge.” In a recent PharmaBoardroom interview, Giancarlo Benelli, SVP and Head of Europe at BeOne Medicines, shared insights into the company’s impressive growth in oncology and hematology and why the Basel Area remains at the core of its European strategy. Since establishing its European headquarters in Basel, BeOne Medicines has expanded its clinical trial program in Europe by nearly 50% and achieved market access across 25 EU countries. Under Benelli’s leadership, the company is driving patient-centered innovation in oncology and hematology. The Basel Area brings together international talent, dynamic start-ups, global pharma companies and world-class academic research, forming a true ecosystem for medical breakthroughs.   🔗 Read the full interview 👉 https://lnkd.in/eZnYvkNh ---- Follow us on #investinbasel Basel Area Business & Innovation #LifeSciences #Innovation #Pharma #Basel #Switzerland #Biotech | Switzerland Global Enterprise | Business Location Switzerland | Swiss Business Hub USA | Swiss Business Hub Korea | Martin Jordan| Annelise Michel | Valentina Francia | Fabio Marelli | ¦Daniel Meier | Bonggeun (Bon) Oh | Shwen Gwee | Kirsten Detrick | Paul Eschmann

186

We are pleased that the European Medicines Agency granted orphan drug designation to KRRO-110, our investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency (#AATD).    This important regulatory milestone highlights the urgent need to bring innovative solutions to people with AATD and takes us one step closer to making that a reality with KRRO-110.     Learn more at: https://lnkd.in/eH6Xx-aN   #KorroBio #OrphanDrugDesignation #RNAEditing 

201

9 Kommentare

📢 We are excited to announce the expansion of our AI Drug Creation collaboration with Absci, marking a new milestone in our shared commitment to accelerate innovation in dermatology. This partnership combines Almirall's deep dermatology expertise with Absci's cutting-edge generative AI platform to unlock new therapeutic approaches.  We are proud to be at the forefront of science, working to explore the newest technological advances to improve unmet needs of dermatological patients. #WeAreAlmirall #AIDrugDiscovery #Dermatology #Innovation

240

2 Kommentare

The European Medicines Agency has granted Orphan Drug Designation to our investigational Bruton’s tyrosine kinase (BTK) inhibitor for IgG4-related disease (IgG4-RD), a rare, immune-mediated disease that has no currently approved medicines.    Read our press release: https://lnkd.in/e3X63JUP

1.227

28 Kommentare

💡 GLP-1s are transforming obesity treatment, so running trials in this space requires a new playbook. In a new video series with Applied Clinical Trials, Parexel's Shipra Patel outlines 5 essential insights every clinical researcher should know: 1️⃣ Support from specialists drives success GLP-1–focused task forces help sponsors stand out in a crowded market. https://lnkd.in/eh2Z4AuS 2️⃣ Cross-collaboration is critical Bridging therapeutic and functional roles improves trial design. https://lnkd.in/efqVj6dq 3️⃣ Real-world insights matter They reveal why patients stop treatment and how to keep them engaged. https://lnkd.in/ev95V5Nr 4️⃣ Data-powered recruitment is essential Use real-world data, such as claims data and TriNetX, to identify where patient pools exist. https://lnkd.in/eg9ui9Ep 5️⃣ Retention is everything Gastrointestinal side effects and unmet weight goals are major drop-out drivers. https://lnkd.in/eXNJCWHy 🎥 Shipra sums it up best! Watch these video snippets to learn how Parexel is helping sponsors stay ahead. #ClinicalResearch #GLP1 #RealWorldEvidence

166

6 Kommentare

Pioneering innovation means being willing to push the boundaries of science to address areas of high unmet need. Learn more about this philosophy from Gianluca and how Alexion’s patient-centered approach is innovating rare disease clinical trial design. http://spr.ly/60494q4rR

329

4 Kommentare

What does it mean for an antibody to take on multiple targets at once? 🎯 In this One Minute Thesis, watch one of our #scientists explain how #MultispecificAntibodies may help create new treatment approaches. [Video description: An AbbVie scientist in the lab explains how multispecific antibodies work. On-screen text reads, “One Minute Thesis, Multispecific Antibodies.”] 

447

23 Kommentare

For over 20 years, ICON has supported the development of biosimilars, complex molecules that are highly comparable to their reference biologic drugs. With the large number of biologics losing patent exclusivity over the next 15 years, it presents an opportunity for developers, especially in the oncology space, payers and patients to benefit from reduced costs and increased market access. Our latest whitepaper outlines the landscape and looks into the future to help you understand what’s coming. Learn more: https://ow.ly/PiIK50WpPWA #oncology #biologics #biosimilar #clinicaltrials

79

5 Kommentare

We’ve received U.S. FDA approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen’s Risperdal Consta®. Our product is eligible for 180-day exclusivity under the FDA’s Competitive Generic Therapy (CGT) designation, and we expect to launch in the fourth quarter of 2025.This milestone reflects our strong R&D and manufacturing expertise, and paves the way for future innovation in microsphere-based long-acting injectables. Learn more: https://lnkd.in/ehwsbQrr *Risperdal Consta® is a registered trademark of Janssen

1.013

#News for #investors and #media: Today ADVANZ PHARMA announces that the European Commission has approved a new biosimilar developed by Alvotech and licensed to ADVANZ PHARMA for distribution across the European Economic Area. This milestone supports their shared mission of broadening access to high-quality, affordable medicines and ensuring patients throughout Europe benefit from timely, sustainable treatment options. More details here: bit.ly/3HkpbME #AdvanzPharma #Partnership #Biosimilars #AccessToMedicines 

290

10 Kommentare

Shaping the Future of Pharma in Switzerland   Switzerland is globally recognized for its cutting-edge pharmaceutical research. What’s less known – but equally impressive – is its role as a powerhouse in medicine manufacturing. Since 1896, pharmaceutical production has been a cornerstone of the Swiss economy. Today, over 190 different medicines are manufactured here, addressing a wide spectrum of health conditions. At BMS Switzerland, we’re proud to contribute to this legacy.   As our Site Head at BMS Boudry, Reto Randegger, puts it: “Switzerland already has excellent innovation ecosystems that we should leverage to focus on high-tech production technologies. This will help us secure the competitiveness of the pharmaceutical industry and produce innovative medicines even more efficiently.”   📘 Want to learn more? Check out the new brochure from Interpharma on Advanced Pharma Manufacturing 👉 https://lnkd.in/d_Xq5Rtq   #AdvancedPharmaManufacturing #PatientImpact #OneBMS #HandInHandForSwitzerland #BMSSwitzerland

68

Together with Bayer | Pharmaceuticals, BlueRock announced positive 36-month data from our Phase I clinical trial for our investigational cell therapy for the treatment of Parkinson's disease. The data were presented on yesterday at the International Congress of Parkinson’s Disease and Movements Disorders. Read the full release: https://lnkd.in/eEqQiQQ4

1.596

15 Kommentare

Behind every data point is a person. Eran Harary, MD, Head of Global Early Clinical Development, Global R&D at Teva, reminds us that the best clinical trials start with a simple question: 𝘞𝘩𝘢𝘵 𝘮𝘢𝘵𝘵𝘦𝘳𝘴 𝘮𝘰𝘴𝘵 𝘵𝘰 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴? From trial design to treatment delivery, his latest article in Clinical Leader shows how patient centricity guides everything we do at Teva. Worth the read: https://ow.ly/3CTk50WCu3c #Tevapharm #PatientCentricity #HealthcareInnovation #PatientExperience #ClinicalResearch

230

5 Kommentare